OTC Cough, Cold and Allergy Medicine Market
OTC Cough, Cold and Allergy Medicine Market Forecast by Drug Type (Antihistamine, Expectorants, Bronchodilators, and Antibiotics), by OTC Channel (Pharmacies, Drug Store, Modern Trade Online Sales), by Dosage (Capsules, Liquid, Lozenges), by Application, and by Region - 2022 to 2032
Analysis of OTC Cough, Cold and Allergy Medicine market covering 30 + countries including analysis of US, Canada, UK, Germany, France, Nordics, GCC countries, Japan, Korea and many more
OTC Cough, Cold and Allergy Medicine Market Outlook
The global OTC cough, cold and allergy medicine market reached a valuation of US$ 36.92 Billion in 2021Y, and is likely to register a Y-o-Y growth rate of 5.0% in 2022, closing at US$ 38.96 Billion. Furthermore, across the 2022 to 2032 period of assessment, growth is expected to accelerate at a whopping 5.5% CAGR, reaching US$ 66.54 Billion.
Over-the-counter drugs are medicines sold directly to a consumer without a requirement for a prescription from a healthcare professional, as opposed to prescription drugs, which may be supplied only to consumers possessing a valid prescription.
| Report Attributes | Details |
|---|---|
| Anticipated Base Year Value (2021) | US$ 36.92 Billion |
| Expected Market Value (2022) | US$ 38.96 Billion |
| Projected Forecast Value (2032) | US$ 66.54 Billion |
| Global Growth Rate (2022 to 2032) | 5.5% CAGR |
| Expected Growth Rate of the US Market (2022 to 2032) | 5.4% CAGR |
| Anticipated Growth Rate of Indian Market (2022 to 2032) | 5.3% CAGR |
| Prominent Players in The Global Market | Sanofi-Aventis; Johnson & Johnson Service Inc.; Reckitt Benckiser Group Plc.; Novartis AG; GlaxoSmithKline Plc.; AstraZeneca Plc.; Pfizer Inc.; Sun Pharmaceutical Industries Ltd.; Prestige Brands Holdings Inc.; Procter & Gamble Co.; Bristol-Myers Squib Co.; Merck & Co.; Allergen |
One of the critical factors that are expected to drive the market growth during the forecast period is the accessibility, affordability, and the presence of a large number of retail stores offering OTC Cough, Cold and Allergy products.
In developed and emerging countries, the increasing investment by the private sector to improve the supply chain through retail stores and other distribution outlets is leading to market growth. According to the Consumer Healthcare Products Association, there are approximately 54,000 pharmacies in the U.S. and more than 750,000 retail outlets selling over-the-counter products.
Additionally, the increasing approvals from regulatory bodies for switching prescription drugs to OTC drugs are fueling the market growth. As the majority of prescription allergy medicines have changed to OTC, there has been a clear shift toward these more convenient and affordable options.
For instance, according to the Consumer Healthcare Products Association (CHPA), numerous prescription allergy medicines have changed to OTC, and there has been a shift toward these drugs owing to their lower costs.
Don't Need a Global Report?
save 40%! on Country & Region specific reports
2017 to 2021 Revenue Analysis of OTC Cough, Cold and Allergy Medicine Market vs. Growth Outlook 2022 to 2032
According to market research and competitive intelligence provider Fact.MR, the OTC Cough, Cold and Allergy Medicine market experienced noteworthy growth, growing at a value CAGR of 2.7% from 2017 to 2021.
Rather than going to a doctor, a large number of people around the world buy OTC (over-the-counter) medicines to treat minor cough, cold or allergy problems. This has been a major factor in the rising sales of OTC bronchodilators and OTC antibiotics.
Moreover, a modern consumer's busy lifestyle makes such medicines even more important, as consulting a doctor for every single health issue can take a long time. Growing percentage of immunocompromised people, rising demand for antihistamine drugs and OTC expectorants, and an increasing worldwide aging population are expected to drive demand for OTC medicines.
The number of pharmacies and over-the-counter (OTC) products available at stores is growing. Cough, cold and allergy medicines are becoming more widely available as a result of these rising numbers.
Latest trends of OTC cough, cold & allergy medicines, increasing demand for OTC cough medicines, allergy medicines, and rising sales of OTC cold medicines are the major factors that are anticipated to boost the growth of the OTC cough, cold & allergy medicine market during the forecast period.
Key Market Drivers Influencing OTC Cough, Cold and Allergy Medicine Industry Expansion
Increasing Shift from Rx to OTC to Bolster Market Growth Prospects
One of the prominent trends in the market is the shift of manufacturers from prescription drugs to OTC. Many manufacturing companies are switching their products from Rx to OTC. For instance, Bayer AG states in their 2019 annual report that as a part of its strategy, the company will change some of its prescriptive products suitable for self-care to OTC. This is anticipated to lead to the higher availability of OTC drugs for various disease conditions in emerging and developed countries.
The other trends in the market include the increasing number of private-label OTC products. The share of private label OTC product sales in the U.S. increased from 26.0% in 2009 to 31.0% in 2018. Also, the rise in online sales in the OTC products and tie-ups between private label OTC manufacturers & e-commerce companies are developing new trends into the market. For instance, in February 2018, Amazon.com, Inc. announced the launch of OTC healthcare products of Perrigo, a private label manufacturer. These upcoming new trends will diversify the market growth during the forecast period.
Wider Availability of OTC Cough, Cold and Allergy Medicines to Propel Market Growth
The global OTC cough, cold and allergy medicines market is being driven by the availability of a large number of OTC products for cough, cold and allergy treatment. Customers can choose from a wide range of products offered by the market's major players. Anti-congestants and cough suppressant tablets, balms, rubs, syrups, and nasal drops are among the products available. Consumers have a greater number of options to choose from because of the companies' wider variety of products.
As a result, consumers are more likely to purchase products that meet their needs, resulting in increased sales of OTC cough, cold & allergy medicines. Furthermore, OTC products are readily available and simple to use. This contributes to the market's expansion.
Other factors, such as the rising trend of self-medication and increased awareness among consumers are expected to boost the demand for cough, cold and allergy medicines globally. In addition, latest innovations in OTC antibiotics and rising opportunities for top manufacturers of OTC cough, cold & allergy medicines for babies, are other factors are fueling the market growth.
More Insights, Lesser Cost (-50% off)
Insights on import/export production,
pricing analysis, and more – Only @ Fact.MR
Key Challenges encountered by OTC Cough, Cold and Allergy Medicine Providers
Wrong Medications Due to Incorrect Self-Diagnosis to Impede the Market Prospects
Some factors that are expected to restrain the global over the counter drugs market growth in the forecast period include the incorrect self-diagnosis leading to the consumption of wrong medicines. Many OTC cough and cold products have led to medication errors and caused adverse effects on the patient’s body.
For instance, a study was published in Academic Pediatrics on the adverse effects caused by OTC cough and cold medicines (CCMs) on the U.S. pediatric population. The study reported that from 2009 to 2016, there were nearly 5,000 cases of adverse effects related to an OTC CCM ingredient. Out of these cases, more than 10.0% were caused due to medication errors.
Additionally, drug abuse and drug addiction practices also pull down the market growth. Cough medicines, diarrhea, and pain relief medicines are some of the common OTC medicines which are used for drug-abusing. According to the Addiction Center and a study published by the Substance Abuse and Mental Health Services Administration (SAMHSA), in the U.S., around 3.1 million young people between the age group of 12 to 25 have misused OTC medications (cold and cough medication) to get high. Furthermore, the use of traditional medicines also acts as a substitute or alternative for over-the-counter drugs market.
Side Effects & Allergies Linked to Usage of OTC Medicines to Limit the Market Growth
Side effects and allergies linked to the use of over-the-counter medicines are likely to hamper future sales. Drug approvals are subject to stringent regulatory requirements, limiting market availability.
In addition, costs associated with the product's manufacturing process are expected to restrain growth of the OTC cough, cold and allergy medicine market over the coming years.
Comparative View of Adjacent OTC Cough, Cold and Allergy Medicine Markets
OTC Cough, Cold and Allergy Medicine Market :
| Attributes | OTC Cough, Cold and Allergy Medicine Market |
|---|---|
| CAGR (2022 to 2032) | 5.5% |
| Market Value (2032) | US$ 66.54 Billion |
| Growth Factor | Rising patent expirations of many drugs resulting in use as OTC drugs and affordable cost of these drugs are the factors that will expand the over the counter (OTC) cough, cold and allergy medicines market. |
| Opportunity | Rising adoption of OTC Cough, Cold and Allergy drugs by many pharmaceutical companies and utilization by general people as compared to the prescription drugs will provide beneficial opportunities to market during the forecast period. |
Bronchodilators Market :
| Attributes | Bronchodilators Market |
|---|---|
| CAGR (2022 to 2032) | 5.2% |
| Market Value (2032) | US$ 56.08 Billion |
| Growth Factor | Surge in prevalence of respiratory disorders such as asthma, chronic obstructive pulmonary disease (COPD), across the globe is the major factor driving the bronchodilators market growth. |
| Opportunity | Rise in disposable income, geriatric population, and increase in awareness of healthcare among population are anticipated to boost the market growth. |
Antihistamines Market :
| Attributes | Antihistamines Market |
|---|---|
| CAGR (2022 to 2032) | 9.25% |
| Market Value (2032) | US$ 620.79 Million |
| Growth Factor | Changing lifestyle and rise in environmental pollution are projected to increase the number of patients affected with seasonal allergies. This is one of the major factors that is expected to fuel the growth of the market over the analysis period. |
| Opportunity | High prevalence of allergies and increase in incidences among children are projected to augment the intake of antihistamines during the forecast period. |
Know thy Competitors
Competitive landscape highlights only certain players
Complete list available upon request
Region-wise Analysis
How will the Growth of OTC Cough, Cold and Allergy Medicine Market Escalate across the US?
Increased Product Awareness to Broaden Market Growth Prospects in the Country
As per Fact.MR, the U.S OTC cough, cold and allergy medicine market is slated to flourish at a CAGR of 5.4% until 2032. The US dominates the global OTC cough, cold and allergy medicine market in terms of revenue. The U.S. market is expected to increase 1.7x by 2032.
Increased knowledge of OTC cough, cold and allergy medicines, their health benefits, and higher willingness to spend money on medication are major drivers anticipated to fuel the demand for OTC cough, cold & allergy medicines in the US. Factors such as improving economic conditions and increased product awareness have a significant impact on OTC cough, cold and allergy medicine sales in the country.
How will India Perform in the Global OTC Cough, Cold and Allergy Medicine Industry Landscape?
Advent of New Product Developments & Acquisitions in India to Boost the Market Growth
According to Fact.MR’s projections, deployment of OTC Cough, Cold and Allergy Medicine across India is forecast to expand at an impressive 5.3% value CAGR from 2022 to 2032. The Indian over-the-counter (OTC) cough, cold and allergy medicines market is moderately competitive in nature. The industry players are focusing on new product developments and acquisition strategies to gain market shares. The developing countries have also opened new growth avenues for pharmaceutical companies.
Thus, the market has different challenges and requires innovative products facilitating new innovative OTC cold and cough drugs. Additionally, the key players have been involved in various strategic alliances, such as acquisitions and collaborations, with the launch of advanced products to secure their position in the market. The major players in the market are Emami Limited, Dabur India Limited, Proctor & Gamble, Abbott Laboratories, and GlaxoSmithKline PLC.
Why is China Offer Increasing Opportunities for Manufacturers of OTC Cough, Cold and Allergy Medicines?
Preference for Pharmaceutical Companies towards OTC Drugs in China to Boost the Market Growth
As per Fact.MR, the OTC cough, cold and allergy medicine market in China is slated to flourish at a CAGR of 5.3% until 2032. Product innovations, high penetration, and the preference of pharmaceutical companies toward OTC drugs over prescription drugs are driving the OTC cough, cold and allergy medicine market growth in China.
Rapid urbanization as well as a rise in disposable income in China, may create a critical mass of people who can access OTC medications. In addition, growth of the OTC cough, cold & allergy medicine market size in China is being bolstered by new channels of accessibility in pharmacies & drug stores and prominent presence of top retailers of OTC antihistamine drugs.
Country-wise Forecast CAGRs for the OTC Cough, Cold and Allergy Medicine Market
| Country | CAGR |
|---|---|
| U.S | 5.4% |
| U.K | 5.1% |
| India | 5.3% |
| China | 5.3% |
| Germany | 5.0% |
Category-wise Insights
Will Bronchodilators Segment remain Dominant in the Drug Type Category?
High Demand for Bronchodilators to Enhance Growth Prospects
By drug type, demand for bronchodilators segment is likely to accelerate the fastest, documenting a value CAGR worth 5.4% from 2022 to 2032, according to Fact.MR. Demand for bronchodilators is expected to increase 1.9x over the forecast period, while demand for other segments is expected to grow slowly. The dominance can be attributed to a higher prevalence of asthma among the global population.
According to the World Health Organization (WHO), In 2019, Asthma affected approximately 262 Mn people worldwide and is responsible for approximately 461,000 deaths. Bronchodilators are medications that open the airways to treat asthma as well as assist in the removal of mucus from the lungs. They are also used to expand the wind pipe, which helps patients with lung infections, bronchial asthma, and chronic obstructive pulmonary disease (COPD) breathe better.
Which is the Most Sought-after OTC Channel Category?
Pharmacies Segment to Dominate the OTC Cough, Cold and Allergy Medicine Market
According to projections published by Fact.MR, by OTC channel, the pharmacies segment is forecast to register a whopping 5.4% value CAGR across the 2022-2032. According to OTC channel analysis of cough, cold and allergy medicines, pharmacies will continue to be the most popular OTC channel for sales of cough, cold and allergy medicines over the next ten years. Pharmaceutical companies are seizing every opportunity to introduce new over-the-counter (OTC) drugs for immediate use.
Use of cough, cold and allergy medicines boosts immunity and aids in fitness maintenance. Immunity and fitness help to prevent a variety of diseases and disorders. Substitutes of OTC cough, cold and allergy medicines are easily available in pharmacies. So, people can easily purchase medicines from a local pharmacy. As a result, more OTC cough, cold and allergy medicines are consumed.
The Start-Up Ecosystem: How key Players are opening Frontiers for Future Growth?
OTC Cough, Cold and Allergy Medicine Market players such as AcareOTC, Myancare, Flexible Pass, Mote Poh, myDoctor, POTENT, WISH, 1-Pharmacy, HealthKart, NetMeds, Capsule, Alto, Pharmacy2U, PromoFarma, and Oziva, among others, are adopting various marketing strategies such as new product launches, geographical expansion, merger and acquisitions, partnerships and collaboration to identify the interest of potential buyers and create a larger customer base. For instance,
- Founded in 2017, Myancare is a provider of OTC as well as Rx drugs. The company is an online teleconsultation platform for multiple diseases. It provides an online platform that allows users to search for doctors and can book an appointment with them. Users can do voice consultation, video consultation, text consultation, and others.
- Founded in 2015, NetMeds is a provider of an online store for medicines and healthcare products. It provides an online platform that offers prescription, over-the-counter drugs, and healthcare and wellness products. Users can directly search for medicine or upload their prescriptions. It allows users to book for diagnostic tests and buy various healthcare products such as skincare, family care, baby care, devices, surgical, and many more.
- Established in 2016, Capsule is a provider of an online pharmacy for delivering OTC and Rx medicines. The platform also coordinates customers with old pharmacy or doctor to get prescriptions and offers hand-delivered same-day medications. The medication is delivered to patient’s home, office, or anywhere.
OTC Cough, Cold and Allergy Medicine Market- Competitive Landscape
Prominent players in the OTC Cough, Cold and Allergy Medicine Industry are taking advantage of the rapidly increasing demand for the OTC Cough, Cold and Allergy Medicine in various applications. To further their outreach, players are relying on collaborations, partnerships and acquisitions with existing small, medium and large-scale vendors. Some prominent market developments are as follows:
- In July 2022, AFT Pharmaceuticals and RooLife Group revealed that they have launched a range of AFT’s over-the-counter (OTC) pharmaceuticals through their store on the China Cross Border E-Commerce (CBEC) online platform Tmall Global.
- In June 2022, Glenmark Pharmaceuticals Ltd has acquired the approved generic versions of certain over-the-counter drugs from Wockhardt Ltd in the United States. The acquisition by the company’s fully-owned subsidiary Glenmark Pharmaceuticals Inc, includes the approved abbreviated new drug applications (ANDAs) for famotidine tablets, 10 mg and 20 mg used to treat and prevent ulcers in the stomach and intestine,
- In June 2021, the FDA approved Astepro Allergy as an over the counter (OTC) drug for the brief alleviation of runny nose, nasal congestion, itchy nose, and other respiratory disorders, according to Bayer.
Key Segments Covered in the OTC Cough, Cold and Allergy Medicine Industry Survey
-
By Drug Type :
- OTC Antihistamine
- OTC Expectorants
- OTC Bronchodilators
- OTC Antibiotics
-
By OTC Channel :
- Pharmacies
- Drug Store
- Modern Trade
- Online
-
By Dosage :
- Capsules
- Liquid
- Tablets
- Lozenges
- Others
- OTC Liquid Cough, Cold & Allergy Solutions
- OTC Liquid Cough, Cold & Allergy Drops
- OTC Liquid Cough, Cold & Allergy Granules
- OTC Liquid Cough, Cold & Allergy Syrup
- OTC Liquid Cough, Cold & Allergy Pills
-
By Application :
- Babies
- Adults
- School-age Children
-
By Region :
- North America
- Latin America
- Europe
- East Asia
- South Asia
- Oceania
- Middle East Africa
Table of Content
- 1. Global Market to Executive Summary
- 2. Global Market Overview
- 3. Global Market Analysis and Forecast By Drug Type
- 3.1. Antihistamine
- 3.2. Expectorants
- 3.3. Bronchodilators
- 3.4. Antibiotics
- 3.5. Others
- 4. Global Market Analysis and Forecast By OTC Channel
- 4.1. Pharmacy
- 4.2. Drug Store
- 4.3. Modern Trade
- 4.4. Online
- 4.5. Other OTC Format
- 5. Global Market Analysis and Forecast By Dosage
- 5.1. Liquid
- 5.2. Capsule
- 5.3. Tablet
- 5.4. Lozenges
- 6. Global Market Analysis and Forecast By Region
- 6.1. North America
- 6.2. Latin America
- 6.3. Europe
- 6.4. Japan
- 6.5. APEJ
- 6.6. MEA
- 7. North America Market Analysis and Forecast, By Country, 2022 to 2032
- 8. Latin America Market Analysis and Forecast, By Country, 2022 to 2032
- 9. Europe Market Analysis and Forecast, By Country, 2022 to 2032
- 10. Japan Market Analysis and Forecast, By Country, 2022 to 2032
- 11. APEJ Market Analysis and Forecast, By Country, 2022 to 2032
- 12. MEA Market Analysis and Forecast, By Country, 2022 to 2032
- 13. Global Market Company/Manufacturers/Distributors/Suppliers Profile and Revenue Projections
- 13.1. Company Share Analysis
- 13.2. Reckitt Benckiser Group Plc.
- 13.3. Johnson & Johnson Service, Inc.
- 13.4. GlaxoSmithKline Plc.
- 13.5. Novartis AG
- 13.6. AstraZeneca Plc.
- 13.7. Sun Pharmaceutical Industries Ltd.
- 13.8. Pfizer Inc.
- 13.9. Prestige Brands Holdings, Inc.
- 13.10. Procter & Gamble Co.
- 13.11. Merck & Co.
- 13.12. Bristol Myers Squibb Co.
- 13.13. Allergan
- 13.14. Sanofi Aventis
- 14. Research Methodology
- 15. Secondary and Primary Sources
- 16. Assumptions and Acronyms
- 17. Disclaimer
Don't Need a Global Report?
save 40%! on Country & Region specific reports
List Of Table
TABLE 01: Global Market Value (US$ Bn), 2017 to 2021
TABLE 02: Global Market Value (US$ Bn), 2022 to 2032
TABLE 03: Global Market Value (US$ Bn) and Y-o-Y, 2017 to 2032
TABLE 04: Global Antihistamine Segment Value (US$ Bn), By Region 2017 to 2021
TABLE 05: Global Antihistamine Segment Value (US$ Bn), By Region 2022 to 2032
TABLE 06: Global Antihistamine Segment Market Share, By Region 2017 to 2021
TABLE 07: Global Antihistamine Segment Market Share, By Region 2022 to 2032
TABLE 08: Global Antihistamine Segment Y-o-Y, By Region 2017 to 2032
TABLE 09: Global Expectorants Segment Value (US$ Bn), By Region 2017 to 2021
TABLE 10: Global Expectorants Segment Value (US$ Bn), By Region 2022 to 2032
TABLE 11: Global Expectorants Segment Market Share, By Region 2017 to 2021
TABLE 12: Global Expectorants Segment Market Share, By Region 2022 to 2032
TABLE 13: Global Expectorants Segment Y-o-Y, By Region 2017 to 2032
TABLE 14: Global Bronchodialators Segment Value (US$ Bn), By Region 2017 to 2021
TABLE 15: Global Bronchodialators Segment Value (US$ Bn), By Region 2022 to 2032
TABLE 16: Global Bronchodialators Segment Market Share, By Region 2017 to 2021
TABLE 17: Global Bronchodialators Segment Market Share, By Region 2022 to 2032
TABLE 18: Global Bronchodialators Segment Y-o-Y, By Region 2017 to 2032
TABLE 19: Global Antibiotics Segment Value (US$ Bn), By Region 2017 to 2021
TABLE 20: Global Antibiotics Segment Value (US$ Bn), By Region 2022 to 2032
TABLE 21: Global Antibiotics Segment Market Share, By Region 2017 to 2021
TABLE 22: Global Antibiotics Segment Market Share, By Region 2022 to 2032
TABLE 23: Global Antibiotics Segment Y-o-Y, By Region 2017 to 2032
TABLE 24: Global Others Segment Value (US$ Bn), By Region 2017 to 2021
TABLE 25: Global Others Segment Value (US$ Bn), By Region 2022 to 2032
TABLE 26: Global Others Segment Market Share, By Region 2017 to 2021
TABLE 27: Global Others Segment Market Share, By Region 2022 to 2032
TABLE 28: Global Others Segment Y-o-Y, By Region 2017 to 2032
TABLE 29: Global Pharmacy Segment Value (US$ Bn), By Region 2017 to 2021
TABLE 30: Global Pharmacy Segment Value (US$ Bn), By Region 2022 to 2032
TABLE 31: Global Pharmacy Segment Market Share, By Region 2017 to 2021
TABLE 32: Global Pharmacy Segment Market Share, By Region 2022 to 2032
TABLE 33: Global Pharmacy Segment Y-o-Y, By Region 2017 to 2032
TABLE 34: Global Drug Store Segment Value (US$ Bn), By Region 2017 to 2021
TABLE 35: Global Drug Store Segment Value (US$ Bn), By Region 2022 to 2032
TABLE 36: Global Drug Store Segment Market Share, By Region 2017 to 2021
TABLE 37: Global Drug Store Segment Market Share, By Region 2022 to 2032
TABLE 38: Global Drug Store Segment Y-o-Y, By Region 2017 to 2032
TABLE 39: Global Modern Trade Segment Value (US$ Bn), By Region 2017 to 2021
TABLE 40: Global Modern Trade Segment Value (US$ Bn), By Region 2022 to 2032
TABLE 41: Global Modern Trade Segment Market Share, By Region 2017 to 2021
TABLE 42: Global Modern Trade Segment Market Share, By Region 2022 to 2032
TABLE 43: Global Modern Trade Segment Y-o-Y, By Region 2017 to 2032
TABLE 44: Global Online Segment Value (US$ Bn), By Region 2017 to 2021
TABLE 45: Global Online Segment Value (US$ Bn), By Region 2022 to 2032
TABLE 46: Global Online Segment Market Share, By Region 2017 to 2021
TABLE 47: Global Online Segment Market Share, By Region 2022 to 2032
TABLE 48: Global Online Segment Y-o-Y, By Region 2017 to 2032
TABLE 49: Global Other OTC Format Segment Value (US$ Bn), By Region 2017 to 2021
TABLE 50: Global Other OTC Format Segment Value (US$ Bn), By Region 2022 to 2032
TABLE 51: Global Other OTC Format Segment Market Share, By Region 2017 to 2021
TABLE 52: Global Other OTC Format Segment Market Share, By Region 2022 to 2032
TABLE 53: Global Other OTC Format Segment Y-o-Y, By Region 2017 to 2032
TABLE 54: Global Liquid Segment Value (US$ Bn), By Region 2017 to 2021
TABLE 55: Global Liquid Segment Value (US$ Bn), By Region 2022 to 2032
TABLE 56: Global Liquid Segment Market Share, By Region 2017 to 2021
TABLE 57: Global Liquid Segment Market Share, By Region 2022 to 2032
TABLE 58: Global Liquid Segment Y-o-Y, By Region 2017 to 2032
TABLE 59: Global Capsule Segment Value (US$ Bn), By Region 2017 to 2021
TABLE 60: Global Capsule Segment Value (US$ Bn), By Region 2022 to 2032
TABLE 61: Global Capsule Segment Market Share, By Region 2017 to 2021
TABLE 62: Global Capsule Segment Market Share, By Region 2022 to 2032
TABLE 63: Global Capsule Segment Y-o-Y, By Region 2017 to 2032
TABLE 64: Global Tablet Segment Value (US$ Bn), By Region 2017 to 2021
TABLE 65: Global Tablet Segment Value (US$ Bn), By Region 2022 to 2032
TABLE 66: Global Tablet Segment Market Share, By Region 2017 to 2021
TABLE 67: Global Tablet Segment Market Share, By Region 2022 to 2032
TABLE 68: Global Tablet Segment Y-o-Y, By Region 2017 to 2032
TABLE 69: Global Lozenges Segment Value (US$ Bn), By Region 2017 to 2021
TABLE 70: Global Lozenges Segment Value (US$ Bn), By Region 2022 to 2032
TABLE 71: Global Lozenges Segment Market Share, By Region 2017 to 2021
TABLE 72: Global Lozenges Segment Market Share, By Region 2022 to 2032
TABLE 73: Global Lozenges Segment Y-o-Y, By Region 2017 to 2032
TABLE 74: North America Market Value (US$ Bn), By Drug Type 2017 to 2021
TABLE 75: North America Market Value (US$ Bn), By Drug Type 2022 to 2032
TABLE 76: North America Market Value (US$ Bn), By OTC Channel 2017 to 2021
TABLE 77: North America Market Value (US$ Bn), By OTC Channel 2022 to 2032
TABLE 78: North America Market Value (US$ Bn), By Dosage 2017 to 2021
TABLE 79: North America Market Value (US$ Bn), By Dosage 2022 to 2032
TABLE 80: Latin America Market Value (US$ Bn), By Drug Type 2017 to 2021
TABLE 81: Latin America Market Value (US$ Bn), By Drug Type 2022 to 2032
TABLE 82: Latin America Market Value (US$ Bn), By OTC Channel 2017 to 2021
TABLE 83: Latin America Market Value (US$ Bn), By OTC Channel 2022 to 2032
TABLE 84: Latin America Market Value (US$ Bn), By Dosage 2017 to 2021
TABLE 85: Latin America Market Value (US$ Bn), By Dosage 2022 to 2032
TABLE 86: Europe Market Value (US$ Bn), By Drug Type 2017 to 2021
TABLE 87: Europe Market Value (US$ Bn), By Drug Type 2022 to 2032
TABLE 88: Europe Market Value (US$ Bn), By OTC Channel 2017 to 2021
TABLE 89: Europe Market Value (US$ Bn), By OTC Channel 2022 to 2032
TABLE 90: Europe Market Value (US$ Bn), By Dosage 2017 to 2021
TABLE 91: Europe Market Value (US$ Bn), By Dosage 2022 to 2032
TABLE 92: Japan Market Value (US$ Bn), By Drug Type 2017 to 2021
TABLE 93: Japan Market Value (US$ Bn), By Drug Type 2022 to 2032
TABLE 94: Japan Market Value (US$ Bn), By OTC Channel 2017 to 2021
TABLE 95: Japan Market Value (US$ Bn), By OTC Channel 2022 to 2032
TABLE 96: Japan Market Value (US$ Bn), By Dosage 2017 to 2021
TABLE 97: Japan Market Value (US$ Bn), By Dosage 2022 to 2032
TABLE 98: APEJ Market Value (US$ Bn), By Drug Type 2017 to 2021
TABLE 99: APEJ Market Value (US$ Bn), By Drug Type 2022 to 2032
TABLE 100: APEJ Market Value (US$ Bn), By OTC Channel 2017 to 2021
TABLE 101: APEJ Market Value (US$ Bn), By OTC Channel 2022 to 2032
TABLE 102: APEJ Market Value (US$ Bn), By Dosage 2017 to 2021
TABLE 103: APEJ Market Value (US$ Bn), By Dosage 2022 to 2032
TABLE 104: MEA Market Value (US$ Bn), By Drug Type 2017 to 2021
TABLE 105: MEA Market Value (US$ Bn), By Drug Type 2022 to 2032
TABLE 106: MEA Market Value (US$ Bn), By OTC Channel 2017 to 2021
TABLE 107: MEA Market Value (US$ Bn), By OTC Channel 2022 to 2032
TABLE 108: MEA Market Value (US$ Bn), By Dosage 2017 to 2021
TABLE 109: MEA Market Value (US$ Bn), By Dosage 2022 to 2032
TABLE 110: US Market Value (US$ Bn), By Drug Type 2017 to 2021
TABLE 111: US Market Value (US$ Bn), By Drug Type 2022 to 2032
TABLE 112: US Market Value (US$ Bn), By OTC Channel 2017 to 2021
TABLE 113: US Market Value (US$ Bn), By OTC Channel 2022 to 2032
TABLE 114: US Market Value (US$ Bn), By Dosage 2017 to 2021
TABLE 115: US Market Value (US$ Bn), By Dosage 2022 to 2032
TABLE 116: Canada Market Value (US$ Bn), By Drug Type 2017 to 2021
TABLE 117: Canada Market Value (US$ Bn), By Drug Type 2022 to 2032
TABLE 118: Canada Market Value (US$ Bn), By OTC Channel 2017 to 2021
TABLE 119: Canada Market Value (US$ Bn), By OTC Channel 2022 to 2032
TABLE 120: Canada Market Value (US$ Bn), By Dosage 2017 to 2021
TABLE 121: Canada Market Value (US$ Bn), By Dosage 2022 to 2032
TABLE 122: Brazil Market Value (US$ Bn), By Drug Type 2017 to 2021
TABLE 123: Brazil Market Value (US$ Bn), By Drug Type 2022 to 2032
TABLE 124: Brazil Market Value (US$ Bn), By OTC Channel 2017 to 2021
TABLE 125: Brazil Market Value (US$ Bn), By OTC Channel 2022 to 2032
TABLE 126: Brazil Market Value (US$ Bn), By Dosage 2017 to 2021
TABLE 127: Brazil Market Value (US$ Bn), By Dosage 2022 to 2032
TABLE 128: Mexico Market Value (US$ Bn), By Drug Type 2017 to 2021
TABLE 129: Mexico Market Value (US$ Bn), By Drug Type 2022 to 2032
TABLE 130: Mexico Market Value (US$ Bn), By OTC Channel 2017 to 2021
TABLE 131: Mexico Market Value (US$ Bn), By OTC Channel 2022 to 2032
TABLE 132: Mexico Market Value (US$ Bn), By Dosage 2017 to 2021
TABLE 133: Mexico Market Value (US$ Bn), By Dosage 2022 to 2032
TABLE 134: Argentina Market Value (US$ Bn), By Drug Type 2017 to 2021
TABLE 135: Argentina Market Value (US$ Bn), By Drug Type 2022 to 2032
TABLE 136: Argentina Market Value (US$ Bn), By OTC Channel 2017 to 2021
TABLE 137: Argentina Market Value (US$ Bn), By OTC Channel 2022 to 2032
TABLE 138: Argentina Market Value (US$ Bn), By Dosage 2017 to 2021
TABLE 139: Argentina Market Value (US$ Bn), By Dosage 2022 to 2032
TABLE 140: Germany Market Value (US$ Bn), By Drug Type 2017 to 2021
TABLE 141: Germany Market Value (US$ Bn), By Drug Type 2022 to 2032
TABLE 142: Germany Market Value (US$ Bn), By OTC Channel 2017 to 2021
TABLE 143: Germany Market Value (US$ Bn), By OTC Channel 2022 to 2032
TABLE 144: Germany Market Value (US$ Bn), By Dosage 2017 to 2021
TABLE 145: Germany Market Value (US$ Bn), By Dosage 2022 to 2032
TABLE 146: UK Market Value (US$ Bn), By Drug Type 2017 to 2021
TABLE 147: UK Market Value (US$ Bn), By Drug Type 2022 to 2032
TABLE 148: UK Market Value (US$ Bn), By OTC Channel 2017 to 2021
TABLE 149: UK Market Value (US$ Bn), By OTC Channel 2022 to 2032
TABLE 150: UK Market Value (US$ Bn), By Dosage 2017 to 2021
TABLE 151: UK Market Value (US$ Bn), By Dosage 2022 to 2032
TABLE 152: France Market Value (US$ Bn), By Drug Type 2017 to 2021
TABLE 153: France Market Value (US$ Bn), By Drug Type 2022 to 2032
TABLE 154: France Market Value (US$ Bn), By OTC Channel 2017 to 2021
TABLE 155: France Market Value (US$ Bn), By OTC Channel 2022 to 2032
TABLE 156: France Market Value (US$ Bn), By Dosage 2017 to 2021
TABLE 157: France Market Value (US$ Bn), By Dosage 2022 to 2032
TABLE 158: Spain Market Value (US$ Bn), By Drug Type 2017 to 2021
TABLE 159: Spain Market Value (US$ Bn), By Drug Type 2022 to 2032
TABLE 160: Spain Market Value (US$ Bn), By OTC Channel 2017 to 2021
TABLE 161: Spain Market Value (US$ Bn), By OTC Channel 2022 to 2032
TABLE 162: Spain Market Value (US$ Bn), By Dosage 2017 to 2021
TABLE 163: Spain Market Value (US$ Bn), By Dosage 2022 to 2032
TABLE 164: Italy Market Value (US$ Bn), By Drug Type 2017 to 2021
TABLE 165: Italy Market Value (US$ Bn), By Drug Type 2022 to 2032
TABLE 166: Italy Market Value (US$ Bn), By OTC Channel 2017 to 2021
TABLE 167: Italy Market Value (US$ Bn), By OTC Channel 2022 to 2032
TABLE 168: Italy Market Value (US$ Bn), By Dosage 2017 to 2021
TABLE 169: Italy Market Value (US$ Bn), By Dosage 2022 to 2032
TABLE 170: Nordic Market Value (US$ Bn), By Drug Type 2017 to 2021
TABLE 171: Nordic Market Value (US$ Bn), By Drug Type 2022 to 2032
TABLE 172: Nordic Market Value (US$ Bn), By OTC Channel 2017 to 2021
TABLE 173: Nordic Market Value (US$ Bn), By OTC Channel 2022 to 2032
TABLE 174: Nordic Market Value (US$ Bn), By Dosage 2017 to 2021
TABLE 175: Nordic Market Value (US$ Bn), By Dosage 2022 to 2032
TABLE 176: Japan Market Value (US$ Bn), By Drug Type 2017 to 2021
TABLE 177: Japan Market Value (US$ Bn), By Drug Type 2022 to 2032
TABLE 178: Japan Market Value (US$ Bn), By OTC Channel 2017 to 2021
TABLE 179: Japan Market Value (US$ Bn), By OTC Channel 2022 to 2032
TABLE 180: Japan Market Value (US$ Bn), By Dosage 2017 to 2021
TABLE 181: Japan Market Value (US$ Bn), By Dosage 2022 to 2032
TABLE 182: China Market Value (US$ Bn), By Drug Type 2017 to 2021
TABLE 183: China Market Value (US$ Bn), By Drug Type 2022 to 2032
TABLE 184: China Market Value (US$ Bn), By OTC Channel 2017 to 2021
TABLE 185: China Market Value (US$ Bn), By OTC Channel 2022 to 2032
TABLE 186: China Market Value (US$ Bn), By Dosage 2017 to 2021
TABLE 187: China Market Value (US$ Bn), By Dosage 2022 to 2032
TABLE 188: India Market Value (US$ Bn), By Drug Type 2017 to 2021
TABLE 189: India Market Value (US$ Bn), By Drug Type 2022 to 2032
TABLE 190: India Market Value (US$ Bn), By OTC Channel 2017 to 2021
TABLE 191: India Market Value (US$ Bn), By OTC Channel 2022 to 2032
TABLE 192: India Market Value (US$ Bn), By Dosage 2017 to 2021
TABLE 193: India Market Value (US$ Bn), By Dosage 2022 to 2032
TABLE 194: Malaysia Market Value (US$ Bn), By Drug Type 2017 to 2021
TABLE 195: Malaysia Market Value (US$ Bn), By Drug Type 2022 to 2032
TABLE 196: Malaysia Market Value (US$ Bn), By OTC Channel 2017 to 2021
TABLE 197: Malaysia Market Value (US$ Bn), By OTC Channel 2022 to 2032
TABLE 198: Malaysia Market Value (US$ Bn), By Dosage 2017 to 2021
TABLE 199: Malaysia Market Value (US$ Bn), By Dosage 2022 to 2032
TABLE 200: Thailand Market Value (US$ Bn), By Drug Type 2017 to 2021
TABLE 201: Thailand Market Value (US$ Bn), By Drug Type 2022 to 2032
TABLE 202: Thailand Market Value (US$ Bn), By OTC Channel 2017 to 2021
TABLE 203: Thailand Market Value (US$ Bn), By OTC Channel 2022 to 2032
TABLE 204: Thailand Market Value (US$ Bn), By Dosage 2017 to 2021
TABLE 205: Thailand Market Value (US$ Bn), By Dosage 2022 to 2032
TABLE 206: Singapore Market Value (US$ Bn), By Drug Type 2017 to 2021
TABLE 207: Singapore Market Value (US$ Bn), By Drug Type 2022 to 2032
TABLE 208: Singapore Market Value (US$ Bn), By OTC Channel 2017 to 2021
TABLE 209: Singapore Market Value (US$ Bn), By OTC Channel 2022 to 2032
TABLE 210: Singapore Market Value (US$ Bn), By Dosage 2017 to 2021
TABLE 211: Singapore Market Value (US$ Bn), By Dosage 2022 to 2032
TABLE 212: Australia Market Value (US$ Bn), By Drug Type 2017 to 2021
TABLE 213: Australia Market Value (US$ Bn), By Drug Type 2022 to 2032
TABLE 214: Australia Market Value (US$ Bn), By OTC Channel 2017 to 2021
TABLE 215: Australia Market Value (US$ Bn), By OTC Channel 2022 to 2032
TABLE 216: Australia Market Value (US$ Bn), By Dosage 2017 to 2021
TABLE 217: Australia Market Value (US$ Bn), By Dosage 2022 to 2032
TABLE 218: GCC Countries Market Value (US$ Bn), By Drug Type 2017 to 2021
TABLE 219: GCC Countries Market Value (US$ Bn), By Drug Type 2022 to 2032
TABLE 220: GCC Countries Market Value (US$ Bn), By OTC Channel 2017 to 2021
TABLE 221: GCC Countries Market Value (US$ Bn), By OTC Channel 2022 to 2032
TABLE 222: GCC Countries Market Value (US$ Bn), By Dosage 2017 to 2021
TABLE 223: GCC Countries Market Value (US$ Bn), By Dosage 2022 to 2032
TABLE 224: South Africa Market Value (US$ Bn), By Drug Type 2017 to 2021
TABLE 225: South Africa Market Value (US$ Bn), By Drug Type 2022 to 2032
TABLE 226: South Africa Market Value (US$ Bn), By OTC Channel 2017 to 2021
TABLE 227: South Africa Market Value (US$ Bn), By OTC Channel 2022 to 2032
TABLE 228: South Africa Market Value (US$ Bn), By Dosage 2017 to 2021
TABLE 229: South Africa Market Value (US$ Bn), By Dosage 2022 to 2032
TABLE 230: Nigeria Market Value (US$ Bn), By Drug Type 2017 to 2021
TABLE 231: Nigeria Market Value (US$ Bn), By Drug Type 2022 to 2032
TABLE 232: Nigeria Market Value (US$ Bn), By OTC Channel 2017 to 2021
TABLE 233: Nigeria Market Value (US$ Bn), By OTC Channel 2022 to 2032
TABLE 234: Nigeria Market Value (US$ Bn), By Dosage 2017 to 2021
TABLE 235: Nigeria Market Value (US$ Bn), By Dosage 2022 to 2032
TABLE 236: Israel Market Value (US$ Bn), By Drug Type 2017 to 2021
TABLE 237: Israel Market Value (US$ Bn), By Drug Type 2022 to 2032
TABLE 238: Israel Market Value (US$ Bn), By OTC Channel 2017 to 2021
TABLE 239: Israel Market Value (US$ Bn), By OTC Channel 2022 to 2032
TABLE 240: Israel Market Value (US$ Bn), By Dosage 2017 to 2021
TABLE 241: Israel Market Value (US$ Bn), By Dosage 2022 to 2032
TABLE 242: Reckitt Benckiser Group Plc. Value (US$ Bn), By Drug Type 2022 to 2032
TABLE 243: Reckitt Benckiser Group Plc. Value (US$ Bn), By OTC Channel 2022 to 2032
TABLE 244: Reckitt Benckiser Group Plc. Value (US$ Bn), By Dosage 2022 to 2032
More Insights, Lesser Cost (-50% off)
Insights on import/export production,
pricing analysis, and more – Only @ Fact.MR
List Of Figures
FIG. 01: Global Market Value (US$ Bn), 2017 to 2021
FIG. 02: Global Market Value (US$ Bn) Forecast, 2022 to 2032
FIG. 03: Global Market Value (US$ Bn) and Y-o-Y, 2017 to 2032
FIG. 04: Global Antihistamine Segment Market Value (US$ Bn) By Region, 2017 to 2021
FIG. 05: Global Antihistamine Segment Market Value (US$ Bn) By Region, 2022 to 2032
FIG. 06: Global Antihistamine Segment Y-o-Y Growth Rate, By Region, 2017 to 2032
FIG. 07: Global Expectorants Segment Market Value (US$ Bn) By Region, 2017 to 2021
FIG. 08: Global Expectorants Segment Market Value (US$ Bn) By Region, 2022 to 2032
FIG. 09: Global Expectorants Segment Y-o-Y Growth Rate, By Region, 2017 to 2032
FIG. 10: Global Bronchodialators Segment Market Value (US$ Bn) By Region, 2017 to 2021
FIG. 11: Global Bronchodialators Segment Market Value (US$ Bn) By Region, 2022 to 2032
FIG. 12: Global Bronchodialators Segment Y-o-Y Growth Rate, By Region, 2017 to 2032
FIG. 13: Global Antibiotics Segment Market Value (US$ Bn) By Region, 2017 to 2021
FIG. 14: Global Antibiotics Segment Market Value (US$ Bn) By Region, 2022 to 2032
FIG. 15: Global Antibiotics Segment Y-o-Y Growth Rate, By Region, 2017 to 2032
FIG. 16: Global Others Segment Market Value (US$ Bn) By Region, 2017 to 2021
FIG. 17: Global Others Segment Market Value (US$ Bn) By Region, 2022 to 2032
FIG. 18: Global Others Segment Y-o-Y Growth Rate, By Region, 2017 to 2032
FIG. 19: Global Pharmacy Segment Market Value (US$ Bn) By Region, 2017 to 2021
FIG. 20: Global Pharmacy Segment Market Value (US$ Bn) By Region, 2022 to 2032
FIG. 21: Global Pharmacy Segment Y-o-Y Growth Rate, By Region, 2017 to 2032
FIG. 22: Global Drug Store Segment Market Value (US$ Bn) By Region, 2017 to 2021
FIG. 23: Global Drug Store Segment Market Value (US$ Bn) By Region, 2022 to 2032
FIG. 24: Global Drug Store Segment Y-o-Y Growth Rate, By Region, 2017 to 2032
FIG. 25: Global Modern Trade Segment Market Value (US$ Bn) By Region, 2017 to 2021
FIG. 26: Global Modern Trade Segment Market Value (US$ Bn) By Region, 2022 to 2032
FIG. 27: Global Modern Trade Segment Y-o-Y Growth Rate, By Region, 2017 to 2032
FIG. 28: Global Online Segment Market Value (US$ Bn) By Region, 2017 to 2021
FIG. 29: Global Online Segment Market Value (US$ Bn) By Region, 2022 to 2032
FIG. 30: Global Online Segment Y-o-Y Growth Rate, By Region, 2017 to 2032
FIG. 31: Global Other OTC Format Segment Market Value (US$ Bn) By Region, 2017 to 2021
FIG. 32: Global Other OTC Format Segment Market Value (US$ Bn) By Region, 2022 to 2032
FIG. 33: Global Other OTC Format Segment Y-o-Y Growth Rate, By Region, 2017 to 2032
FIG. 34: Global Liquid Segment Market Value (US$ Bn) By Region, 2017 to 2021
FIG. 35: Global Liquid Segment Market Value (US$ Bn) By Region, 2022 to 2032
FIG. 36: Global Liquid Segment Y-o-Y Growth Rate, By Region, 2017 to 2032
FIG. 37: Global Capsule Segment Market Value (US$ Bn) By Region, 2017 to 2021
FIG. 38: Global Capsule Segment Market Value (US$ Bn) By Region, 2022 to 2032
FIG. 39: Global Capsule Segment Y-o-Y Growth Rate, By Region, 2017 to 2032
FIG. 40: Global Tablet Segment Market Value (US$ Bn) By Region, 2017 to 2021
FIG. 41: Global Tablet Segment Market Value (US$ Bn) By Region, 2022 to 2032
FIG. 42: Global Tablet Segment Y-o-Y Growth Rate, By Region, 2017 to 2032
FIG. 43: Global Lozenges Segment Market Value (US$ Bn) By Region, 2017 to 2021
FIG. 44: Global Lozenges Segment Market Value (US$ Bn) By Region, 2022 to 2032
FIG. 45: Global Lozenges Segment Y-o-Y Growth Rate, By Region, 2017 to 2032
FIG. 46: North America Market Value (US$ Bn), By Drug Type 2017 to 2021
FIG. 47: North America Market Value (US$ Bn), By Drug Type 2022 to 2032
FIG. 48: North America Market Value (US$ Bn), By OTC Channel 2017 to 2021
FIG. 49: North America Market Value (US$ Bn), By OTC Channel 2022 to 2032
FIG. 50: North America Market Value (US$ Bn), By Dosage 2017 to 2021
FIG. 51: North America Market Value (US$ Bn), By Dosage 2022 to 2032
FIG. 52: Latin America Market Value (US$ Bn), By Drug Type 2017 to 2021
FIG. 53: Latin America Market Value (US$ Bn), By Drug Type 2022 to 2032
FIG. 54: Latin America Market Value (US$ Bn), By OTC Channel 2017 to 2021
FIG. 55: Latin America Market Value (US$ Bn), By OTC Channel 2022 to 2032
FIG. 56: Latin America Market Value (US$ Bn), By Dosage 2017 to 2021
FIG. 57: Latin America Market Value (US$ Bn), By Dosage 2022 to 2032
FIG. 58: Europe Market Value (US$ Bn), By Drug Type 2017 to 2021
FIG. 59: Europe Market Value (US$ Bn), By Drug Type 2022 to 2032
FIG. 60: Europe Market Value (US$ Bn), By OTC Channel 2017 to 2021
FIG. 61: Europe Market Value (US$ Bn), By OTC Channel 2022 to 2032
FIG. 62: Europe Market Value (US$ Bn), By Dosage 2017 to 2021
FIG. 63: Europe Market Value (US$ Bn), By Dosage 2022 to 2032
FIG. 64: Japan Market Value (US$ Bn), By Drug Type 2017 to 2021
FIG. 65: Japan Market Value (US$ Bn), By Drug Type 2022 to 2032
FIG. 66: Japan Market Value (US$ Bn), By OTC Channel 2017 to 2021
FIG. 67: Japan Market Value (US$ Bn), By OTC Channel 2022 to 2032
FIG. 68: Japan Market Value (US$ Bn), By Dosage 2017 to 2021
FIG. 69: Japan Market Value (US$ Bn), By Dosage 2022 to 2032
FIG. 70: APEJ Market Value (US$ Bn), By Drug Type 2017 to 2021
FIG. 71: APEJ Market Value (US$ Bn), By Drug Type 2022 to 2032
FIG. 72: APEJ Market Value (US$ Bn), By OTC Channel 2017 to 2021
FIG. 73: APEJ Market Value (US$ Bn), By OTC Channel 2022 to 2032
FIG. 74: APEJ Market Value (US$ Bn), By Dosage 2017 to 2021
FIG. 75: APEJ Market Value (US$ Bn), By Dosage 2022 to 2032
FIG. 76: MEA Market Value (US$ Bn), By Drug Type 2017 to 2021
FIG. 77: MEA Market Value (US$ Bn), By Drug Type 2022 to 2032
FIG. 78: MEA Market Value (US$ Bn), By OTC Channel 2017 to 2021
FIG. 79: MEA Market Value (US$ Bn), By OTC Channel 2022 to 2032
FIG. 80: MEA Market Value (US$ Bn), By Dosage 2017 to 2021
FIG. 81: MEA Market Value (US$ Bn), By Dosage 2022 to 2032
Know thy Competitors
Competitive landscape highlights only certain players
Complete list available upon request
- FAQs -
How will the US market for OTC Cough, Cold and Allergy Medicine flourish until 2032?
As per Fact.MR’s projections, the market for OTC Cough, Cold and Allergy Medicine in the US will likely expand at a 5.4% CAGR.
What will be the growth scenario for the market in India until 2032?
India is poised to yield a CAGR of 5.3% Billion with respect to OTC Cough, Cold and Allergy Medicine in 2032.
Which is the most preferred OTC Channel category of OTC Cough, Cold and Allergy Medicine?
By OTC Channel, the Pharmacies Segment is expected to dominate the market, documenting a 5.4% value CAGR.
At what percentage will the industry expand during the 2022-2032 period of assessment?
From 2022 to 2032, the OTC Cough, Cold and Allergy Medicine industry is poised to flourish at a 5.5% CAGR.
What is the expected closing market value for OTC Cough, Cold and Allergy Medicine in 2032?
By 2032, the OTC Cough, Cold and Allergy Medicine landscape is slated to reach a valuation of US$ 66.54 Billion.
By drug type, which segment is likely to experience the fastest growth rate?
Bronchodilators Segment is expected to grow the fastest, at a CAGR of 5.4%.
At what value will the OTC Cough, Cold and Allergy Medicine market close in 2022?
As of 2022, Fact.MR expects the OTC Cough, Cold and Allergy Medicine industry to be valued at US$ 38.96 Billion.
From 2017-2021, what was the documented growth rate for the OTC Cough, Cold and Allergy Medicine market?
According to Fact.MR, a CAGR of 2.7% was recorded for the OTC Cough, Cold and Allergy Medicine market from 2017-2021.
What was the market worth for OTC Cough, Cold and Allergy Medicine in 2021?
As of 2021, the OTC Cough, Cold and Allergy Medicine market was valued at US$ 36.92 Billion.
OTC Cough, Cold and Allergy Medicine Market